

Erratum to: Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

André J. Scheen

Published online: 22 October 2014
© Springer International Publishing Switzerland 2014

Erratum to: Clin Pharmacokinet (2014) 53(9):773–785
DOI 10.1007/s40262-014-0157-y

Page 778, Table 3: The last three rows which previously read:

	Alogliptin 25 mg ^b (n = 2,679)	Placebo (n = 2,701)	
ALT >3 × ULN	46 (1.7)	64 (2.4)	0.10
AST >3 × ULN	43 (1.6)	48 (1.8)	0.67

Should read

	Alogliptin 25 mg ^b (n = 2,701)	Placebo (n = 2,679)	
ALT >3 × ULN	64 (2.4)	46 (1.7)	0.10
AST >3 × ULN	48 (1.8)	43 (1.6)	0.67

The online version of the original article can be found under
doi:[10.1007/s40262-014-0157-y](https://doi.org/10.1007/s40262-014-0157-y).

A. J. Scheen (✉)
Division of Diabetes, Nutrition and Metabolic Disorders,
Department of Medicine, University of Liège, Liège, Belgium
e-mail: andre.scheen@chu.ulg.ac.be

A. J. Scheen
Division of Clinical Pharmacology, Center for Interdisciplinary
Research on Medicines (CIRM), CHU Sart Tilman (B35),
University of Liège, 4000 Liège 1, Belgium